Viatris Inc. says it “continues to have the opportunity” to launch its Breyna generic version of AstraZeneca’s Symbicort (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler in 2022 – ahead of a key patent-infringement trial scheduled for 19 May in a court in West Virginia.
On the other hand, the company’s first-quarter investor presentation offers a more conservative 2023 projected launch, “reflecting current management estimates,...




